Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study

Table 4 Treatment Response among Re-Treated Patients

	Daratumumab re-treated patients¹
	First treatment segment	Second treatment segment
	N = 19	N = 19
Best response achieved per IMWG criteria², n (%)
Stringent complete response	0 (0.0)	0 (0.0)
Complete response	0 (0.0)	1 (5.3)
Very good partial response	5 (26.3)	2 (10.5)
Partial response	7 (36.8)	6 (31.6)
Minimal response	0 (0.0)	1 (5.3)
Stable disease	5 (26.3)	1 (5.3)
Progressive disease	1 (5.3)	6 (31.6)
Clinical relapse	0 (0.0)	0 (0.0)
Other	0 (0.0)	0 (0.0)
Unknown/not available	1 (5.3)	2 (10.5)
Patients with known response rate, n (%)	18 (94.7)	17 (89.5)
Overall response rate³, n (%)	12 (66.7)	9 (52.9)
Very good partial response or better, n (%)	5 (27.8)	3 (17.6)
Months from regimen start to best response date, mean ± SD [median]	5.3 ± 4.7 [3.3]	2.0 ± 1.1 [1.8]

Abbreviations: IMWG: International Myeloma Working Group; SD: standard deviation
Notes
[1] Re-treatment was defined as the resumption of a daratumumab-based treatment regimen following a ≥ 90-day period during which daratumumab was not administered. Patients were excluded if they had a stem cell transplant during the gap between the daratumumab-based treatment regimens or during these regimens
[2] Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17 [15]:e328-e346
[3] Overall response rate defined as partial response or better among patients with known response rate

ISSN: 1471-2407